Michael Gelband’s Amneal Pharmaceuticals AMRX Stock Holding History

Michael Gelband’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.45M	Buy	256,843 +95,143	+59%	+$1.3M	0.03%	536
2026 Q1	$2.01M	Sell	161,700 -664,299	-80%	-$8.92M	0.02%	781
2025 Q4	$10.4M	Buy	825,999 +83,186	+11%	+$952K	0.08%	251
2025 Q3	$7.44M	Buy	742,813 +211,032	+40%	+$1.89M	0.08%	282
2025 Q2	$4.3M	Buy	+531,781	New	+$4.01M	0.04%	468
2025 Q1	–	Sell	-108,267	Closed	-$857K	–	1429
2024 Q4	$857K	Buy	+108,267	New	+$908K	0.01%	993
2024 Q3	–	Sell	-111,969	Closed	-$711K	–	1593
2024 Q2	$711K	Buy	+111,969	New	+$711K	﹤0.01%	1126
2023 Q4	–	Sell	-47,484	Closed	-$200K	–	1430
2023 Q3	$200K	Buy	+47,484	New	+$177K	﹤0.01%	1525
2022 Q1	–	Sell	-23,292	Closed	-$112K	–	2160
2021 Q4	$112K	Buy	+23,292	New	+$116K	﹤0.01%	1940
2021 Q3	–	Sell	-42,032	Closed	-$215K	–	2069
2021 Q2	$215K	Buy	+42,032	New	+$239K	﹤0.01%	1942

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Michael Gelband's AMRX Position: Q2 2026 in Review

Michael Gelband increased its Amneal Pharmaceuticals (AMRX) stake by 59% in Q2 2026, buying an estimated $1.3M and bringing the position to 256,843 shares worth $4.45M. The position accounts for 0.03% of the portfolio, ranked #536.

Michael Gelband first reported a position in AMRX in Q2 2021 and has held it in 10 quarters since. The position peaked at $10.4M in Q4 2025. 305 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Michael Gelband held 256,843 shares of Amneal Pharmaceuticals worth $4.45M as of Q2 2026.
Michael Gelband bought 95,143 Amneal Pharmaceuticals shares in Q2 2026, an estimated $1.3M.
Amneal Pharmaceuticals made up 0.03% of Michael Gelband's portfolio in Q2 2026, its #536 holding.
Michael Gelband first reported a position in Amneal Pharmaceuticals in Q2 2021 and has held it in 10 quarters since.
Michael Gelband's Amneal Pharmaceuticals position peaked at $10.4M in Q4 2025.
305 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.